Neurologic comorbidities in Schizophrenia

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 6, 2005, Pages 34-46

  Nasrallah, Henry A ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

AKATHISIA; AWARENESS; BRAIN ELECTROPHYSIOLOGY; BRAIN MALFORMATION; BRAIN SIZE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CRANIOFACIAL MALFORMATION; DROWSINESS; DYSKINESIA; ELECTROENCEPHALOGRAPHY; EPILEPSY; EVOKED AUDITORY RESPONSE; GAIT DISORDER; HUMAN; MEMORY DISORDER; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PRIORITY JOURNAL; REVIEW; RIGIDITY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SENSORY DYSFUNCTION; TARDIVE DYSKINESIA; WORKING MEMORY;

ABNORMALITIES; ANTIPSYCHOTIC AGENTS; BRAIN; CLINICAL TRIALS; COGNITION DISORDERS; COMORBIDITY; HUMANS; MOVEMENT DISORDERS; NERVOUS SYSTEM DISEASES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 24144496847     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (159)

1. Kasai K, Iwanami A, Yamasue H, et al. Neuroanatomy and neurophysiology in schizophrenia. Neurosci Res 2002;43:93-110
2. Harrison PJ. The neuropathological effects of antipsychotic drugs. Schizophr Res 1999;40:87-99
3. Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry 1998;172:110-120
4. Wright IC, Rabe-Hesketh S, Woodruff PW, et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000;157:16-25
5. McCarley RW, Wible CG, Frumin M, et al. MRI anatomy of schizophrenia. Biol Psychiatry 1999;45:1099-1119
6. Torrey EF. Studies of individuals with schizophrenia never treated with antipsychotic medications: a review. Schizophr Res 2002;58:101-115
7. Cahn W, Pol HE, Lems EB, et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch Gen Psychiatry 2002;59: 1002-1010
8. Hulshoff Pol HE, Schnack HG, Bertens MG, et al. Volume changes in gray matter in patients with schizophrenia. Am J Psychiatry 2002;159: 244-250
9. Hulshoff Pol HE, Schnack HG, Mandl RC, et al. Focal gray matter density changes in schizophrenia. Arch Gen Psychiatry 2001;58:1118-1125
10. McCarley RW, Salisbury DF, Hirayasu Y, et al. Association between smaller left posterior superior temporal gyrus volume on magnetic resonance imaging and smaller left temporal P300 amplitude in first-episode schizophrenia. Arch Gen Psychiatry 2002;59:321-331
11. Hirayasu Y, McCarley RW, Salisbury DF, et al. Planum temporale and Heschl gyrus volume reduction in schizophrenia: a magnetic resonance imaging study of first-episode patients. Arch Gen Psychiatry 2000;57: 692-699
12. Lawrie SM, Whalley HC, Abukmeil SS, et al. Temporal lobe volume changes in people at high risk of schizophrenia with psychotic symptoms. Br J Psychiatry 2002;181:138-143
13. Milev P, Ho BC, Arndt S, et al. Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: a prospective longitudinal study with 5-year follow-up. Biol Psychiatry 2003;54: 608-615
14. Harrison PJ. The neuropathology of schizophrenia: a critical review of the data and their interpretation. Brain 1999;122 (pt 4):593-624
15. Weiss AP, Zalesak M, De Witt I, et al. Impaired hippocampal function during the detection of novel words in schizophrenia. Biol Psychiatry 2004;55:668-675
16. Chance SA, Esiri MM, Crow TJ. Amygdala volume in schizophrenia: post-mortem study and review of magnetic resonance imaging findings. Br J Psychiatry 2002;180:331-338
17. Nasrallah HA, Schwarzkopf SB, Olson SC, et al. Gender differences in schizophrenia on MRI brain scans. Schizophr Bull 1990;16:205-210
18. Schwarzkopf SB, Nasrallah HA, Olson SC, et al. Family history and brain morphology in schizophrenia: an MRI study. Psychiatry Res 1991;40: 49-60
19. Downhill JE Jr, Buchsbaum M, Wei T, et al. Shape and size of the corpus callosum in schizophrenia and schizotypal personality disorder. Schizophr Res 2000;42:193-208
20. Tibbo P, Nopoulos P, Arndt S, et al. Corpus callosum shape and size in male patients with schizophrenia. Biol Psychiatry 1998;44:405-412
21. Seidman LJ, Faraone SV, Goldstein JM, et al. Thalamic and amygdala-hippocampal volume reductions in first-degree relatives of patients with schizophrenia: an MRI-based morphometric analysis. Biol Psychiatry 1999;46:941-954
22. McDonald B, Highley JR, Walker MA, et al. Anomalous asymmetry of fusiform and parahippocampal gyrus gray matter in schizophrenia: a postmortem study. Am J Psychiatry 2000;157:40-47
23. White T, Andreasen NC, Nopoulos P, et al. Gyrification abnormalities in childhood- and adolescent-onset schizophrenia. Biol Psychiatry 2003; 54:418-426
24. Niznikiewicz M, Donnino R, McCarley RW, et al. Abnormal angular gyms asymmetry in schizophrenia. Am J Psychiatry 2000;157:428-437
25. Vogeley K, Schneider-Axmann T, Pfeiffer U, et al. Disturbed gyrification of the prefrontal region in male schizophrenic patients: a morphometric postmortem study. Am J Psychiatry 2000;157:34-39
26. Barch DM, Carter CS, Braver TS, et al. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry 2001;58:280-288
27. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001;98:6917-6922
28. Goldberg TE, Egan MF, Gscheidle T, et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003; 60:889-896
29. Perlstein WM, Carter CS, Noll DC, et al. Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am J Psychiatry 2001;158:1105-1113
30. Perlstein WM, Dixit NK, Carter CS, et al. Prefrontal cortex dysfunction mediates deficits in working memory and prepotent responding in schizophrenia. Biol Psychiatry 2003;53:25-38
31. Quintana J, Wong T, Ortiz-Portillo E, et al. Prefrontal-posterior parietal networks in schizophrenia: primary dysfunctions and secondary compensations. Biol Psychiatry 2003;53:12-24
32. Weinberger DR, Egan MF, Bertolino A, et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001;50:825-844
33. Potkin SG, Alva G, Fleming K, et al. A PET study of the pathophysiology of negative symptoms in schizophrenia. Am J Psychiatry 2002;159: 227-237
34. McNeil TF, Cantor-Graae E, Ismail B. Obstetric complications and congenital malformation in schizophrenia. Brain Res Brain Res Rev 2000;31: 166-178
35. Ismail B, Cantor-Graae E, McNeil TF. Minor physical anomalies in schizophrenic patients and their siblings. Am J Psychiatry 1998;155: 1695-1702
36. Trixler M, Tenyi T, Csabi G, et al. Minor physical anomalies in schizophrenia and bipolar affective disorder. Schizophr Res 2001;52:195-201
37. Ismail B, Cantor-Graae E, McNeil TF. Minor physical anomalies in schizophrenia: cognitive, neurological and other clinical correlates. J Psychiatr Res 2000;34:45-56
38. Marenco S, Weinberger DR. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 2000;12:501-527
39. Schiffman J, Ekstrom M, LaBrie J, et al. Minor physical anomalies and schizophrenia spectrum disorders: a prospective investigation. Am J Psychiatry 2002;159:238-243
40. Cannon M, Jones PB, Murray RM. Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry 2002;159: 1080-1092
41. Cannon TD, van Erp TG, Rosso IM, et al. Fetal hypoxia and structural brain abnormalities in schizophrenic patients, their siblings, and controls. Arch Gen Psychiatry 2002;59:35-41
42. Matsumoto H, Takei N, Saito H, et al. Childhood-onset schizophrenia and obstetric complications: a case-control study. Schizophr Res 1999; 38:93-99
43. Eliez S, Schmitt JE, White CD, et al. Children and adolescents with velocardiofacial syndrome: a volumetric MRI study. Am J Psychiatry 2000;157:409-415
44. Eliez S, Blasey CM, Schmitt EJ, et al. Velocardiofacial syndrome: are structural changes in the temporal and mesial temporal regions related to schizophrenia? Am J Psychiatry 2001;158:447-453
45. Kuperberg G, Heckers S. Schizophrenia and cognitive function. Curr Opin Neurobiol 2000;10:205-210
46. Mohs R. Cognition in schizophrenia: natural history, assessment, and clinical importance. Neuropsychopharmacology 1999;21:S203-S210
47. Riley EM, McGovern D, Mockler D, et al. Neuropsychological functioning in first-episode psychosis: evidence of specific deficits. Schizophr Res 2000;43:47-55
48. Lussier I, Slip E. Memory and attention deficits in drug naive patients with schizophrenia. Schizophr Res 2001;48:45-55
49. Gold S, Arndt S, Nopoulos P, et al. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry 1999;156:1342-1348
50. Green MF, Marder SR, Glynn SM, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 2002;51:972-978
51. Sharma T. Characterisation of cognitive impairment in schizophrenia. Lancet Neurol 2003;2:10
52. Fujii DE, Wylie AM. Neurocognition and community outcome in schizophrenia: long-term predictive validity. Schizophr Res 2002; 59:219-223
53. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr Res 2000;45:175-184
54. Verdoux H, Liraud F, Assens F, et al. Social and clinical consequences of cognitive deficits in early psychosis: a two-year follow-up study of first-admitted patients. Schizophr Res 2002;56:149-159
55. Liu SK, Chiu CH, Chang CJ, et al. Deficits in sustained attention in schizophrenia and affective disorders: stable versus state-dependent markers. Am J Psychiatry 2002;159:975-982
56. Weiss AP, Schacter DL, Goff DC, et al. Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia. Biol Psychiatry 2003;53:48-55
57. Manschreck TC, Maher BA, Candela SF, et al. Impaired verbal memory is associated with impaired motor performance in schizophrenia: relationship to brain structure. Schizophr Res 2000;43:21-32
58. Elvevag B, Joscelyn JE, Goldberg TE. Probed recall for serial order deficits in short-term memory in schizophrenic patients. Schizophr Res 2002; 59:127-135
59. Gabrovska VS, Laws KR, Sinclair J, et al. Visual object processing in schizophrenia: evidence for an associative agnosic deficit. Schizophr Res 2003;59:277-286
60. Perry W, Light GA, Davis H, et al. Schizophrenia patients demonstrate a dissociation on declarative and non-declarative memory tests. Schizophr Res 2000;46:167-174
61. Hartman M, Steketee MC, Silva S, et al. Working memory and schizophrenia: evidence for slowed encoding. Schizophr Res 2002;59:99-113
62. Honey GD, Bullmore ET, Sharma T. De-coupling of cognitive performance and cerebral functional response during working memory in schizophrenia. Schizophr Res 2002;53:45-56
63. Okada A. Deficits of spatial working memory in chronic schizophrenia. Schizophr Res 2002;53:75-82
64. Tek C, Gold J, Blaxton T, et al. Visual perceptual and working memory impairments in schizophrenia. Arch Gen Psychiatry 2002;59:146-153
65. Spindler KA, Sullivan EV, Menon V, et al. Deficits in multiple systems of working memory in schizophrenia. Schizophr Res 1997;27:1-10
66. Lysaker PH, Bryson GJ, Lancaster RS, et al. Insight in schizophrenia: associations with executive function and coping style. Schizophr Res 2002;59:41-47
67. Drake RJ, Lewis SW. Insight and neurocognition in schizophrenia. Schizophr Res 2003;62:165-173
68. Dollfus S, Lombardo C, Benali K, et al. Executive/attentional cognitive functions in schizophrenic patients and their parents: a preliminary study. Schizophr Res 2002;53:93-99
69. Szeszko PR, Strous RD, Goldman RS, et al. Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia. Am J Psychiatry 2002;159:217-226
70. Kasai K, Yamada H, Kamio S, et al. Neuromagnetic correlates of impaired automatic categorical perception of speech sounds in schizophrenia. Schizophr Res 2002;59:159-172
71. Nicolson R, Lenane M, Singaracharlu S, et al. Premorbid speech and language impairments in childhood-onset schizophrenia: association with risk factors. Am J Psychiatry 2000;157:794-800
72. Elvevag B, Weinstock DM, Akil M, et al. A comparison of verbal fluency tasks in schizophrenic patients and normal controls. Schizophr Res 2001; 51:119-126
73. David AS, Malmberg A, Brandt L, et al. IQ and risk for schizophrenia: a population-based cohort study. Psychol Med 1997;27:1311-1323
74. Sanderson TL, Doody GA, Best J, et al. Correlations between clinical and historical variables, and cerebral structural variables in people with mild intellectual disability and schizophrenia. J Intellect Disabil Res 2001;45 (pt 2):89-98
75. Sanderson TL, Best JJ, Doody GA, et al. Neuroanatomy of comorbid schizophrenia and learning disability: a controlled study. Lancet 1999;354:1867-1871
76. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-1028
77. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 2001;48:17-28
78. Pallanti S, Quercioli L, Pazzagli A. Effects of clozapine on awareness of illness and cognition in schizophrenia. Psychiatry Res 1999;86:239-249
79. Potkin SG, Fleming K, Jin Y, et al. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol 2001;21:479-483
80. Purdon SE, Jones BD, Slip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000;57:249-258
81. Purdon SE, Malla A, Labelle A, et al. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001;26:137-149
82. Smith RC, Infante M, Singh A, et al. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. Int J Neuropsychopharmacol 2001;4:239-250
83. Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002;53:239-248
84. Velligan DI, Prihoda TJ, Sui D, et al. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry 2003; 64:524-531
85. Townsend LA, Norman RM, Malla AK, et al. Changes in cognitive functioning following comprehensive treatment for first episode patients with schizophrenia spectrum disorders. Psychiatry Res 2002;113:69-81
86. Good KP, Kiss I, Buiteman C, et al. Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br J Psychiatry 2002;181:S45-S49
87. Manschreck TC, Redmond DA, Candela SF, et al. Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. J Neuropsychiatry Clin Neurosci 1999;11:481-489
88. Purdon SE, Labelle A, Boulay L. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophr Res 2001;48:57-67
89. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 1996;41:35S-40S
90. Meltzer HY, Lee MA. Quetiapine improves cognitive function in schizophrenia. Presented at the International Congress on Schizophrenia Research; April 28-May 2, 2001; Whistler, British Columbia, Canada
91. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152: 1724-1729
92. Fenn DS, Moussaoui D, Hoffman WF, et al. Movements in never-medicated schizophrenics: a preliminary study. Psychopharmacology (Berl) 1996;123:206-210
93. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 2000;61(suppl 4):10-14
94. Gervin M, Browne S, Lane A, et al. Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. Am J Psychiatry 1998;155:1202-1206
95. McCreadie RG, Ohaeri JU. Movement disorder in never and minimally treated Nigerian schizophrenic patients. Br J Psychiatry 1994;164: 184-189
96. Puri BK, Barnes TR, Chapman MJ, et al. Spontaneous dyskinesia in first episode schizophrenia. J Neurol Neurosurg Psychiatry 1999;66:76-78
97. Rogers D. The motor disorders of severe psychiatric illness: a conflict of paradigms. Br J Psychiatry 1985;147:221-232
98. McCreadie RG, Thara R, Kamath S, et al. Abnormal movements in never-medicated Indian patients with schizophrenia. Br J Psychiatry 1996;168:221-226
99. Gerlach J, Casey DE. Tardive dyskinesia. Acta Psychiatr Scand 1988;77:369-378
100. Llorca PM, Chereau I, Bayle FJ, et al. Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 2002;17:129-138
101. Caligiuri MP, Lohr JB, Panton D, et al. Extrapyramidal motor abnormalities associated with late-life psychosis. Schizophr Bull 1993;19: 747-754
102. Honer WG, Kopala LC, Rabinowitz J. Prevalence and severity of movement disorders in first-episode, neuroleptic non-exposed patients with psychosis. Schizophr Res 2002;53(suppl 1):11
103. Kopala LC, Good KP, Fredrikson D, et al. Risperidone in first-episode schizophrenia: improvement in symptoms and pre-existing extrapyramidal signs. Int J Psychiatry Clin Prac 1998;2:S19-S25
104. Cortese L, Norman R, Townsend L, et al. Motor abnormalities and clinical correlates in drug-naive, first-episode patients with schizophrenia [abstract]. Schizophr Res 2002;53:55
105. Walker E, Lewis N, Loewy R, et al. Motor dysfunction and risk for schizophrenia. Dev Psychopathol 1999;11:509-523
106. Morgante L, Epifanio A, Spina E, et al. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 2002;23(suppl 2):S89-S90
107. Kuenstler U, Juhnhold U, Knapp WH, et al. Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs. Psychiatry Res 1999; 90:31-39
108. Manson AJ, Schrag A, Lees AJ. Low-dose olanzapine for levodopa induced dyskinesias. Neurology 2000;55:795-799
109. Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997;17:308-313
110. Kopala L, Rabinowitz J, Emsley R, et al. Extrapyramidal signs and symptoms (EPS) in recent onset schizophrenia: a comparison of risperidone and haloperidol. Presented at the Schizophrenia Research Winter Workshop on Schizophrenia; Feb 7-13, 2004; Davos, Switzerland
111. Emsley R, Turner HJ, Schronen J, et al. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 2004;65:696-701
112. Katzenschlager R, Manson AJ, Evans A, et al. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J Neurol Neurosurg Psychiatry 2004;75:295-297
113. Wijnen HH, van der Heijden FM, van Schendel FM, et al. Quetiapine in the elderly with parkinsonism and psychosis. Eur Psychiatry 2003;18: 372-373
114. Baron MS, Dalton WB. Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease [letter]. Mov Disord 2003; 18:1208-1209
115. Kopala L, Milliken H, Whitehorn D, et al. Long-term clinical effectiveness of quetiapine in first-episode psychosis. Presented at the 17th annual congress of the European College of Neuropharmacology; Oct 9-13, 2004; Stockholm, Sweden
116. Chamberlain GHA, Russell JG. The EEGs of the relatives of schizophrenics. J Ment Sci 1952;98:654-659
117. Ellingson RJ. The incidence of EEG abnormality among patients with mental disorders of apparently nonorganic origin: a critical review. Am J Psychiatry 1954;111:263-275
118. Finley KH, Campbell CM. Electroencephalography in schizophrenia. Am J Psychiatry 1941;98:374-381
119. Greenblatt M. Age and electroencephalographic abnormality in neuropsychiatric patients: a study of 1593 cases. Am J Psychiatry 1944;164: 253-255
120. Koenig T, Lehmann D, Saito N, et al. Decreased functional connectivity of EEG theta-frequency activity in first-episode, neuroleptic-naive patients with schizophrenia: preliminary results. Schizophr Res 2001;50: 55-60
121. Koukkou M, Federspiel A, Braker E, et al. An EEG approach to the neurodevelopmental hypothesis of schizophrenia studying schizophrenics, normal controls and adolescents. J Psychiatr Res 2000;34:57-73
122. Boutros NN, Torello MW, Barker BA, et al. The P50 evoked potential component and mismatch detection in normal volunteers: implications for the study of sensory gating. Psychiatry Res 1995;57:83-88
123. Erwin RJ, Turetsky BI, Moberg P, et al. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr Res 1998;33:157-167
124. Gonul AS, Suer C, Coburn K, et al. Effects of olanzapine on auditory P300 in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:173-177
125. Turetsky BI, Colbath EA, Gur RE. P300 subcomponent abnormalities in schizophrenia, 1: physiological evidence for gender and subtype specific differences in regional pathology. Biol Psychiatry 1998;43:84-96
126. Boutros N, Nasrallah H, Leighty R, et al. Auditory evoked potentials, clinical vs. research applications. Psychiatry Res 1997;69:183-195
127. Jeon YW, Polich J. P300 asymmetry in schizophrenia: a meta-analysis. Psychiatry Res 2001;104:61-74
128. Ford JM, Mathalon DH, Kalba S, et al. N1 and P300 abnormalities in patients with schizophrenia, epilepsy, and epilepsy with schizophrenialike features. Biol Psychiatry 2001;49:848-860
129. Frodl-Bauch T, Gallinat J, Meisenzahl EM, et al. P300 subcomponents reflect different aspects of psychopathology in schizophrenia. Biol Psychiatry 1999;45:116-126
130. Higashima M, Nagasawa T, Kawasaki Y, et al. Auditory P300 amplitude as a state marker for positive symptoms in schizophrenia: cross-sectional and retrospective longitudinal studies. Schizophr Res 2002;59:147-157
131. Turetsky B, Colbath EA, Gur RE. P300 subcomponent abnormalities in schizophrenia, 2: longitudinal stability and relationship to symptom change. Biol Psychiatry 1998;43:31-39
132. Lauer CJ, Schreiber W, Pollmacher T, et al. Sleep in schizophrenia: a polysomnographic study on drug-naive patients. Neuropsychopharmacology 1997;16:51-60
133. Lauer CJ, Krieg JC. Slow-wave sleep and ventricular size: a comparative study in schizophrenia and major depression. Biol Psychiatry 1998; 44:121-128
134. Knott V, Labelle A, Jones B, et al. Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment. Schizophr Res 2001;50:41-53
135. Light GA, Geyer MA, Clementz BA, et al. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 2000;157:767-771
136. Umbricht D, Javitt D, Novak G, et al. Effects of clozapine on auditory event-related potentials in schizophrenia. Biol Psychiatry 1998;44: 716-725
137. Hyde TM, Weinberger DR. Seizures and schizophrenia. Schizophr Bull 1997;23:611-622
138. Makikyro T, Karvonen JT, Hakko H, et al. Comorbidity of hospital-treated psychiatric and physical disorders with special reference to schizophrenia: a 28 year follow-up of the 1966 northern Finland general population birth cohort. Public Health 1998;112:221-228
139. Manchanda R. Psychiatric disorders in epilepsy: clinical aspects. Epilepsy Behav 2002;3:39-45
140. Marsh L, Rao V. Psychiatric complications in patients with epilepsy: a review. Epilepsy Res 2002;49:11-33
141. Adachi N, Onuma T, Nishiwaki S, et al. Inter-ictal and post-ictal psychoses in frontal lobe epilepsy: a retrospective comparison with psychoses in temporal lobe epilepsy. Seizure 2000;9:328-335
142. Christodoulou C, Koutroumanidis M, Hennessy MJ, et al. Postictal psychosis after temporal lobectomy. Neurology 2002;59:1432-1435
143. Tebartz van Elst L, Baeumer D, Lemieux L, et al. Amygdala pathology in psychosis of epilepsy: a magnetic resonance imaging study in patients with temporal lobe epilepsy. Brain 2002;125:140-149
144. Amann BL, Pogarell O, Mergl R, et al. EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects. Hum Psychopharmacol 2003;18:641-646
145. Guieu R, Samuelian JC, Coulouvrat H. Objective evaluation of pain perception in patients with schizophrenia. Br J Psychiatry 1994;164: 253-255
146. Dazzan P, Murray RM. Neurological soft signs in first-episode psychosis: a systematic review. Br J Psychiatry 2002;181:S50-S57
147. Sullivan EV, Fama R, Shear PK, et al. Motor sequencing deficits in schizophrenia: a comparison with Parkinson's disease. Neuropsychology 2001;15:342-350
148. Boks MP, Russo S, Knegtering R, et al. The specificity of neurological signs in schizophrenia: a review. Schizophr Res 2000;43:109-116
149. Cuesta MJ, Peralta V, Zarzuela A, et al. Neurological soft-signs in psychosis: threshold criteria for discriminating normal controls and for predicting cognitive impairment. Schizophr Res 2002;58:263-271
150. Chen EY, Lam LC, Chen RY, et al. Neurological signs and sustained attention impairment in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2001;251:1-5
151. Egan MF, Hyde TM, Bonomo JB, et al. Relative risk of neurological signs in siblings of patients with schizophrenia. Am J Psychiatry 2001;158:1827-1834
152. Ismail BT, Cantor-Graae E, Cardenal S, et al. Neurological abnormalities in schizophrenia: clinical, etiological and demographic correlates. Schizophr Res 1998;30:229-238
153. Bachoud-Levi AC, Ergis AM, Cesaro P, et al. Dissociation between distal and proximal left limb agraphia and agraphesthesia in a patient with a callosal disconnection syndrome. Cortex 2000;36:351-363
154. Barnes TR, Crichton P, Nelson HE, et al. Primitive (developmental) reflexes, tardive dyskinesia and intellectual impairment in schizophrenia. Schizophr Res 1995;16:47-52
155. Youssef HA, Waddington JL. Primitive (developmental) reflexes and diffuse cerebral dysfunction in schizophrenia and bipolar affective disorder: overrepresentation in patients with tardive dyskinesia. Biol Psychiatry 1988;23:791-796
156. Sommer I, Aleman A, Ramsey N, et al. Handedness, language lateralisation and anatomical asymmetry in schizophrenia: meta-analysis. Br J Psychiatry 2001;178:344-351
157. Highley JR, Esiri MM, McDonald B, et al. Anomalies of cerebral asymmetry in schizophrenia interact with gender and age of onset: a post-mortem study. Schizophr Res 1998;34:13-25
158. Loberg EM, Jorgensen HA, Hugdahl K. Functional brain asymmetry and attentional modulation in young and stabilised schizophrenic patients: a dichotic listening study. Psychiatry Res 2002;109:281-287
159. Satz P, Green MF. Atypical handedness in schizophrenia: some methodological and theoretical issues. Schizophr Bull 1999;25:63-78